Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice

Table 1

Characteristics of the study participants: patients on eplerenone, spironolactone, or other antihypertensive drugs during the last claim month of stable treatment (≥ six months of treatment with the same drugs, N = 160,992).

Characteristic	Patients on eplerenone	Patients on spironolactone	Patients on other antihypertensive drugs
	(N = 1,204)	(N = 2,074)	(N = 157,718)
Age (years), Mean (SD)	57.3 (10.7)	59.8 (10.9)	59.8 (9.7)
Female, N (%)	331 (27.5)	876 (42.2)	59,952 (38.0)
Comorbidities, N (%)
Cardiovascular disease	578 (48.0)	1,239 (59.7)	51,046 (32.4)
Diabetes	556 (46.2)	1,111 (53.6)	54,553 (34.6)
Heart failure	336 (27.9)	997 (48.1)	12,256 (7.8)
Renal disease	135 (11.2)	247 (11.9)	11,295 (7.2)
Concomitant antihypertensive drugs, N (%)
Beta blocker	375 (31.1)	828 (39.9)	21,884 (13.9)
Diuretics	317 (26.3)	896 (43.2)	18,352 (11.6)
Eplerenone	1,204 (100.0)	4 (0.2)	0(0)
Spironolactone	4 (0.3)	2,074 (100.0)	0(0)
ACE inhibitor	103 (8.6)	358 (17.3)	10,596 (6.7)
Alpha blocker	81 (6.7)	86 (4.1)	5,568 (3.5)
CCB	816 (67.8)	854 (41.2)	107,496 (68.2)
ARB	770 (64.0)	947 (45.7)	99,840 (63.3)
Others	25 (2.1)	13 (0.6)	976 (0.6)

ACE inhibitor: angiotensin-converting-enzyme inhibitor, CCB: calcium channel blocker, and ARB: angiotensin II receptor blocker. Note: four patients were prescribed both eplerenone and spironolactone.
SD: standard deviation.